Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human umbilical cord mesenchymal stem cells (Shenzhen Hornetcorn Biotechnology Co., Ltd., 825ee0)
- Development stage
- Unknown
- Lead developer
- Shenzhen Hornetcorn Bio-technology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Hepatic Artery Intervention
01
Overview
This cell-based biologic therapy consists of human umbilical cord mesenchymal stem cells (hUC-MSC) and is being developed by Shenzhen Hornetcorn Bio-technology Company, LTD. These multipotent adult stem cells are characterized by their immunomodulatory, anti-fibrotic, and regenerative capabilities. The therapy is currently under investigation in a Phase 1 clinical trial for the treatment of hepatic cirrhosis (liver cirrhosis). Administered via intravenous infusion or hepatic artery intervention, the hUC-MSCs are intended to migrate to the damaged liver tissue and promote repair through paracrine signaling, immune modulation, and the reduction of fibrotic activity, thereby potentially restoring liver function.
- Other names
- hUC-MSChuman umbilical cord-mesenchymal stem cells
Beyond the preview
Go deeper on human umbilical cord mesenchymal stem cells (Shenzhen Hornetcorn Biotechnology Co., Ltd., 825ee0).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human umbilical cord mesenchymal stem cells (Shenzhen Hornetcorn Biotechnology Co., Ltd., 825ee0).